Nonetheless, Diabetes Poland, in the recently released guidelines, recommends the combination therapy of SGLT2 inhibitors with GLP-1-R agonists and metformin in patients with ASVCD or multiple risk factors regardless of the target HbA1C. This evidence concerns the gene SLC5A2 and diabetes mellitus.